Yunnan Hongxiang Yixintang (002727) - Net Assets
Based on the latest financial reports, Yunnan Hongxiang Yixintang (002727) has net assets worth CN¥7.64 Billion CNY (≈ $1.12 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥15.69 Billion ≈ $2.30 Billion USD) and total liabilities (CN¥8.05 Billion ≈ $1.18 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Yunnan Hongxiang Yixintang to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥7.64 Billion |
| % of Total Assets | 48.68% |
| Annual Growth Rate | 23.26% |
| 5-Year Change | 11.76% |
| 10-Year Change | 198.52% |
| Growth Volatility | 28.61 |
Yunnan Hongxiang Yixintang - Net Assets Trend (2009–2025)
This chart illustrates how Yunnan Hongxiang Yixintang's net assets have evolved over time, based on quarterly financial data. See 002727 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Yunnan Hongxiang Yixintang (2009–2025)
The table below shows the annual net assets of Yunnan Hongxiang Yixintang from 2009 to 2025. For live valuation and market cap data, see Yunnan Hongxiang Yixintang stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥7.46 Billion ≈ $1.09 Billion |
-2.56% |
| 2024-12-31 | CN¥7.65 Billion ≈ $1.12 Billion |
-2.84% |
| 2023-12-31 | CN¥7.88 Billion ≈ $1.15 Billion |
+4.64% |
| 2022-12-31 | CN¥7.53 Billion ≈ $1.10 Billion |
+12.81% |
| 2021-12-31 | CN¥6.67 Billion ≈ $976.40 Million |
+15.43% |
| 2020-12-31 | CN¥5.78 Billion ≈ $845.87 Million |
+25.77% |
| 2019-12-31 | CN¥4.60 Billion ≈ $672.56 Million |
+13.50% |
| 2018-12-31 | CN¥4.05 Billion ≈ $592.57 Million |
+9.63% |
| 2017-12-31 | CN¥3.69 Billion ≈ $540.54 Million |
+47.87% |
| 2016-12-31 | CN¥2.50 Billion ≈ $365.55 Million |
+9.91% |
| 2015-12-31 | CN¥2.27 Billion ≈ $332.61 Million |
+9.14% |
| 2014-12-31 | CN¥2.08 Billion ≈ $304.77 Million |
+98.33% |
| 2013-12-31 | CN¥1.05 Billion ≈ $153.67 Million |
+29.52% |
| 2012-12-31 | CN¥810.77 Million ≈ $118.64 Million |
+28.94% |
| 2011-12-31 | CN¥628.80 Million ≈ $92.01 Million |
+26.41% |
| 2010-12-31 | CN¥497.43 Million ≈ $72.79 Million |
+89.30% |
| 2009-12-31 | CN¥262.78 Million ≈ $38.45 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Yunnan Hongxiang Yixintang's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 9022.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥4.50 Billion | 61.59% |
| Other Components | CN¥2.80 Billion | 38.41% |
| Total Equity | CN¥7.30 Billion | 100.00% |
Yunnan Hongxiang Yixintang Competitors by Market Cap
The table below lists competitors of Yunnan Hongxiang Yixintang ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shanghai Runda Med Tech Co
SHG:603108
|
$917.82 Million |
|
Matrix Design Co. Ltd. A
SHE:301365
|
$917.94 Million |
|
Pharming Group NV
AS:PHARM
|
$917.94 Million |
|
Tian Jin Motor Dies Co Ltd
SHE:002510
|
$918.02 Million |
|
Lotte Tour Dev
KO:032350
|
$917.06 Million |
|
Jiangsu Riying Electns Co Ltd
SHG:603286
|
$917.00 Million |
|
Kayne Anderson BDC, Inc.
NYSE:KBDC
|
$916.96 Million |
|
Northeast Pharmaceutical Group Co Ltd
SHE:000597
|
$916.75 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Yunnan Hongxiang Yixintang's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,491,014,022 to 7,303,470,419, a change of -187,543,603 (-2.5%).
- Net income of 263,432,452 contributed positively to equity growth.
- Dividend payments of 304,891,343 reduced retained earnings.
- Other comprehensive income decreased equity by 366,768,341.
- Other factors increased equity by 220,683,630.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥263.43 Million | +3.61% |
| Dividends Paid | CN¥304.89 Million | -4.17% |
| Other Comprehensive Income | CN¥-366.77 Million | -5.02% |
| Other Changes | CN¥220.68 Million | +3.02% |
| Total Change | CN¥- | -2.50% |
Book Value vs Market Value Analysis
This analysis compares Yunnan Hongxiang Yixintang's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.86x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 14.57x to 0.86x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | CN¥0.73 | CN¥10.71 | x |
| 2010-12-31 | CN¥1.32 | CN¥10.71 | x |
| 2011-12-31 | CN¥1.60 | CN¥10.71 | x |
| 2012-12-31 | CN¥2.07 | CN¥10.71 | x |
| 2013-12-31 | CN¥2.68 | CN¥10.71 | x |
| 2014-12-31 | CN¥4.57 | CN¥10.71 | x |
| 2015-12-31 | CN¥4.37 | CN¥10.71 | x |
| 2016-12-31 | CN¥4.80 | CN¥10.71 | x |
| 2017-12-31 | CN¥7.10 | CN¥10.71 | x |
| 2018-12-31 | CN¥7.12 | CN¥10.71 | x |
| 2019-12-31 | CN¥8.09 | CN¥10.71 | x |
| 2020-12-31 | CN¥10.06 | CN¥10.71 | x |
| 2021-12-31 | CN¥11.11 | CN¥10.71 | x |
| 2022-12-31 | CN¥12.48 | CN¥10.71 | x |
| 2023-12-31 | CN¥12.98 | CN¥10.71 | x |
| 2024-12-31 | CN¥12.65 | CN¥10.71 | x |
| 2025-12-31 | CN¥12.47 | CN¥10.71 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Yunnan Hongxiang Yixintang utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.61%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.52%
- • Asset Turnover: 1.11x
- • Equity Multiplier: 2.14x
- Recent ROE (3.61%) is below the historical average (15.05%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 32.86% | 5.83% | 2.12x | 2.65x | CN¥59.03 Million |
| 2010 | 21.03% | 5.56% | 1.67x | 2.26x | CN¥54.00 Million |
| 2011 | 21.59% | 6.07% | 1.70x | 2.10x | CN¥72.33 Million |
| 2012 | 22.64% | 6.42% | 1.86x | 1.89x | CN¥101.91 Million |
| 2013 | 23.00% | 6.79% | 1.71x | 1.98x | CN¥136.13 Million |
| 2014 | 14.28% | 6.71% | 1.51x | 1.41x | CN¥89.04 Million |
| 2015 | 15.23% | 6.51% | 1.27x | 1.84x | CN¥118.96 Million |
| 2016 | 14.16% | 5.65% | 1.04x | 2.41x | CN¥103.74 Million |
| 2017 | 11.44% | 5.45% | 1.08x | 1.93x | CN¥53.32 Million |
| 2018 | 12.88% | 5.68% | 1.25x | 1.82x | CN¥116.51 Million |
| 2019 | 13.14% | 5.76% | 1.32x | 1.73x | CN¥144.43 Million |
| 2020 | 13.70% | 6.24% | 1.36x | 1.62x | CN¥213.42 Million |
| 2021 | 14.01% | 6.32% | 1.02x | 2.18x | CN¥263.81 Million |
| 2022 | 13.60% | 5.79% | 1.08x | 2.18x | CN¥267.38 Million |
| 2023 | 7.09% | 3.16% | 1.04x | 2.15x | CN¥-225.16 Million |
| 2024 | 1.52% | 0.63% | 1.07x | 2.25x | CN¥-634.96 Million |
| 2025 | 3.61% | 1.52% | 1.11x | 2.14x | CN¥-466.91 Million |
Industry Comparison
This section compares Yunnan Hongxiang Yixintang's net assets metrics with peer companies in the Pharmaceutical Retailers industry.
Industry Context
- Industry: Pharmaceutical Retailers
- Average net assets among peers: $1,914,661,916
- Average return on equity (ROE) among peers: 9.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Yunnan Hongxiang Yixintang (002727) | CN¥7.64 Billion | 32.86% | 1.05x | $917.76 Million |
| Cachet Pharmaceutical Co Ltd (002462) | $3.20 Billion | 8.25% | 1.88x | $535.28 Million |
| Luyan Pharma Co Ltd (002788) | $3.32 Billion | 8.45% | 3.03x | $621.39 Million |
| Ji Yao Holding Group Co Ltd (300108) | $384.36 Million | 7.83% | 0.04x | $20.47 Million |
| ShuYu Civilian Pharmacy Corp. Ltd. (301017) | $1.91 Billion | 6.00% | 1.61x | $777.53 Million |
| Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) | $1.68 Billion | 4.07% | 0.78x | $278.33 Million |
| Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A (301408) | $2.06 Billion | 6.68% | 1.34x | $900.84 Million |
| Shanghai No1 Pharmacy Co Ltd (600833) | $669.57 Million | 7.05% | 0.61x | $316.33 Million |
| Dashenlin Pharm Grp Co Ltd (603233) | $3.09 Billion | 17.22% | 1.12x | $2.69 Billion |
| Laobaixing Pharmacy (603883) | $916.46 Million | 17.54% | 1.38x | $1.31 Billion |
About Yunnan Hongxiang Yixintang
Yixintang Pharmaceutical Group Co., Ltd., together with its subsidiary, engages in the pharmaceutical retail chain and pharmaceutical distribution business. The company is involved in the wholesale, retail, leasing, and operation of medical devices; sale of food, disinfectants, disinfection equipment, sanitary products and disposable medical products, household appliances, adult toys, agricultura… Read more